• Precautions for Use of Serplulimab

  Serplulimab (a PD-1 inhibitor) mainly causes immune-related adverse reactions, infusion reactions, and systemic symptoms such as fatigue. As an antine···【Read More】

  Update: 2026-02-13Source: Haiou HealthViews: 79

• Side Effects of Serplulimab

  Serplulimab (a PD-1 inhibitor) mainly causes immune-related adverse reactions, infusion reactions, and systemic symptoms such as fatigue. As an antine···【Read More】

  Update: 2026-02-13Source: Haiou HealthViews: 78

• Dosage and Administration of Serplulimab

  The dosage and administration of serplulimab (a PD‑1 inhibitor) must follow clinical guidelines strictly.IndicationsIt is mainly indicated for the tre···【Read More】

  Update: 2026-02-13Source: Haiou HealthViews: 106

• Serplulimab Injection

  Serplulimab injection is an anti-tumor drug of the PD-1 inhibitor class. It activates the immune system by blocking the PD-1/PD-L1 signaling pathway, ···【Read More】

  Update: 2026-02-13Source: Haiou HealthViews: 81

• Efficacy and Side Effects of Tunlametinib

  Tunlametinib is a targeted therapeutic drug classified as a MEK inhibitor, primarily used to inhibit the growth and spread of cancer cells. Its core e···【Read More】

  Update: 2026-02-12Source: Haiou HealthViews: 77

• Side Effects of Tunlametinib

  Tunlametinib is a targeted therapy belonging to the MEK inhibitor class, primarily used to treat specific types of cancer (e.g., melanoma). Its common···【Read More】

  Update: 2026-02-12Source: Haiou HealthViews: 76

• How Many Days Does One Box of Turalenib Last?

  The number of days Turalenib can be taken per box depends on the drug specification and the prescribed dosage. Generally, if one box contains 30 table···【Read More】

  Update: 2026-02-12Source: Haiou HealthViews: 79

• Tunlametinib Capsules Prescribing Information

  Tunlametinib capsules are an oral targeted therapeutic agent for tumors harboring specific gene mutations, mainly indicated for the treatment of malig···【Read More】

  Update: 2026-02-12Source: Haiou HealthViews: 78

• Drug-Drug Interactions of Toripalimab

  Toripalimab is a PD-1 inhibitor classified as an immune checkpoint inhibitor, mainly used for the treatment of various malignant tumors (e.g., melanom···【Read More】

  Update: 2026-02-11Source: Haiou HealthViews: 75

• Precautions for Toripalimab

  Toripalimab (anti-PD-1 monoclonal antibody) is mainly indicated for the treatment of advanced solid tumors (such as melanoma, nasopharyngeal carcinoma···【Read More】

  Update: 2026-02-11Source: Haiou HealthViews: 76

• Side Effects of Toripalimab

  Toripalimab is a PD-1 inhibitor, a type of tumor immunotherapeutic drug, mainly used for the treatment of malignant tumors such as melanoma and nasoph···【Read More】

  Update: 2026-02-11Source: Haiou HealthViews: 73

• How many vials of Toripalimab are used per dose

  The recommended dose of toripalimab is usually 3 mg per kg of body weight, administered once every 2 weeks. The exact number of vials per dose is calc···【Read More】

  Update: 2026-02-11Source: Haiou HealthViews: 77

• Toripalimab Instruction Manual

  Toripalimab is an anticancer drug classified as a PD-1 inhibitor. Its main ingredient is a monoclonal antibody targeting the PD-1 receptor on the surf···【Read More】

  Update: 2026-02-11Source: Haiou HealthViews: 77

• Who is Disitamab Vedotin Suitable For?

  Disitamab vedotin is an anti-HER2 antibody-drug conjugate (ADC). It is mainly indicated for patients with advanced solid tumors confirmed to have HER2···【Read More】

  Update: 2026-02-10Source: Haiou HealthViews: 81

• Important Usage Instructions for Disitamab Vedotin

  Disitamab vedotin is a targeted antibody-drug conjugate (ADC) indicated for the treatment of HER2-expressing locally advanced or metastatic solid tumo···【Read More】

  Update: 2026-02-10Source: Haiou HealthViews: 76